Slide 1: Vita Life Sciences Limited Preliminary Year End Results
Vita Life Sciences Limited ASX Code: VSC Preliminary Year End Results 31 December 2009
Slide 2: Brands
Brands Australia Y Y Malaysia Y Y Singapore Y Thailand Y Y China Y Y Indonesia Y Vietnam Y 1
Slide 3: Sales Trend and Debt Levels
Sales Trend and Debt Levels 30.1 $ ' Millions 17.0 15.5 11.8 11.1 Events 2000 2003 2005 2007 2009 Listed on ASX Pan Recall & Delisted Eddie Tie appointed MD Relisted on ASX Health division profitable Debt ($ ’m) 3.5 18.3 21.4 0.8 1.3 • Recovery has been achieved • Currently in profitable growth phas
Slide 4: Product Reach
Product Reach • In Australia –products are sold in over 600 health food stores; • In Malaysia – products are sold in 3 main channels over-the-counter (>800 stores), no-frills and multi-level marketing (2,000 distributors); • In Singapore – VH products are sold in over 200 stores • In China, Thailand
Slide 5: Group's Business Strategy
Group’s Business Strategy • OTC – Australia, Malaysia, Singapore (Established markets) • OTC – Thailand (2007), China (2008), Vietnam (2010), Indonesia (2011) • MLM – Malaysia (2007), Singapore & Thailand (2010), Indonesia (2011), Vietnam (2013) • Profit vs sensible market share • 50 million populat
Slide 6: Sales Revenue
Sales Revenue 18 17.0 16 14.4 14 • Sales grew by 18.5% 11.8 12 11.1 11.1 in 2009 (2008: 21.3%) A$ million 10 8 6 • Established business 4 2 grew by 17.3% (2008: 0 20.6%) 2005 2006 2007 2008 2009 5
Slide 7: Sales Revenue - Segment
Sales Revenue - Segment 2009 2008 Singapore Singapore 20% 22% Others Others Australia 1% Australia 1% 46% 49% Malaysia Malaysia 30% 31% • Sales growth y-o-y for Australia, Malaysia and Singapore were 26.5%, 10.9% and 3.3% respectively 6
Slide 8: Normalised Profit
Normalised Profit Income Statement ($ m) 2009 2008 EBIT (0.1) 0.5 Add / (less): Pan TGA Claim (costs) / receipts 0.6 (1.0) Normalised EBIT 0.5 (0.5) Interest expense (0.2) (0.2) Normalised net profit after tax 0.3 (0.8) Normalised EPS 0.6 cts (1.4) cts 7
Slide 9: Normalised EBIT
Normalised EBIT 0.50 (3.0) (1.8) (0.5) (0.6) - 0.5 -0.50 A$ million -1.00 -1.50 -2.00 -2.50 -3.00 Year 2005 2006 2007 2008 2009 1. Excluding proceeds from Pan Liquidator of $0.70 million, $0.01 million and $1.04 million in 2005, 2007 and 2008 respectively 2. Excluding profit on disposal of Cyclophar
Slide 10: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet At 31 December ($ m) 2009 2008 Current assets 6.6 6.2 Non-current assets 2.2 2.4 Total assets 8.8 8.6 Current liabilities (4.9) (4.8) Non-current liabilities (0.0) (0.0) Total liabilities (4.9) (4.8) Net assets 3.9 3.8 9
Slide 11: Other
Other • Group has an equity interest of 6.3% (20.1% profit share) in a property project in Malaysia; • Project has a positive cash flow; • No funding required from Group. 10
Slide 12: Health Division Outlook for 2010
Health Division Outlook for 2010 • 2009 sales trends forecast to continue • Continue to invest 30% – 40% of operating profits in new businesses • Improved profitability after investment in new businesses 11
Slide 13: Shareholder Information at 31 Jan. '10
Shareholder Information at 31 Jan. ‘10 Ordinary shares Percentage Ten largest quoted equity security holders Number held of shares issued Stinoc Pty Limited 8.04 14.8% Chemical Trustee Limited 7.56 13.9% Barleigh Wells Limited 7.37 13.6% Eddie L S Tie 3.35 6.2% Normandy Finance & Investments Asia Li
Slide 14: Thank You
Thank You 24 February 2010 © Powered Templates.com